Related Experiment Video
Updated: Jun 20, 2026
Laparoscopic Pancreatoduodenectomy for Pancreatic Cancer Using In-Situ No-Touch Isolation Technique
Published on: February 2, 2022
Surgical resection after TNFerade therapy for locally advanced pancreatic cancer
Manpreet K Chadha1, Alan Litwin, Charles Levea
1Department of Medicine, Roswell Park Cancer Institute and State University of New York at Buffalo, Buffalo, NY, USA.
Context:
Treatment of pancreatic cancer remains a major oncological challenge and survival is dismal. Most patients, present with advanced disease at diagnosis and are not candidates for curative resection. Preoperative chemoradiation may downstage and improve survival in locally advanced pancreatic cancer. This has prompted investigators to look for novel neoadjuvant therapies. Gene therapy for pancreatic cancer is a novel investigational approach that may have promise. TNFerade is a replication deficient adenovirus vector carrying the human tumor necrosis factor (TNF)-alpha gene regulated under control of a radiation-inducible gene promoter. Transfection of tumor cells with TNFerade maximizes the antitumor effect of TNF-alpha under influence of radiation leading to synergistic effects in preclinical studies.
Case Report:
We describe a case of locally advanced unresectable pancreatic cancer treated with a novel multimodal approach utilizing gene therapy with TNFerade and concurrent chemoradiation that was followed by successful surgical resection.
Conclusion:
Neoadjuvant TNFerade based chemoradiation therapy may be a useful adjunct to treatment of locally advanced pancreatic cancer.
Insights
Novel gene therapy with TNFerade and chemoradiation offers a promising neoadjuvant treatment for locally advanced pancreatic cancer, enabling successful surgical resection in a recent case study.
Area of Science:
- Oncology
- Gene Therapy
- Surgical Oncology
Background:
- Pancreatic cancer presents a significant challenge with poor survival rates, often diagnosed at advanced stages unsuitable for resection.
- Novel neoadjuvant therapies are being investigated to improve outcomes for locally advanced pancreatic cancer.
- Gene therapy, specifically using TNFerade, shows potential as a novel approach.
Observation:
- A case of locally advanced, unresectable pancreatic cancer was treated with a multimodal strategy.
- The treatment involved gene therapy with TNFerade combined with concurrent chemoradiation.
- This neoadjuvant approach facilitated successful surgical resection.
Findings:
- TNFerade, an adenovirus vector carrying the tumor necrosis factor (TNF)-alpha gene, demonstrated synergistic effects with radiation in preclinical models.
- The combination of TNFerade and chemoradiation was effective in downstaging the tumor.
- Successful surgical resection was achieved post-neoadjuvant therapy.
Implications:
- Neoadjuvant TNFerade-based chemoradiation may serve as a valuable adjunct therapy for locally advanced pancreatic cancer.
- This multimodal approach could improve resectability rates and patient survival.
- Further investigation into gene therapy combinations for pancreatic cancer is warranted.